AI Insight
People with Lynch syndrome face elevated colorectal cancer risk due to hereditary factors. The CAPP2 study demonstrated that 600 milligrams of daily aspirin (acetylsalicylic acid) significantly reduces long-term colorectal cancer risk in this high-risk population. The new international CaPP3 study, published in The Lancet Gastroenterology & Hepatology, suggests that a lower dose of 100 milligrams daily may provide similar cancer-preventive benefits with fewer side effects, particularly reduced bleeding complications.
Why it matters
This research could make aspirin-based cancer prevention more accessible and safer for people with Lynch syndrome by establishing that a lower, more tolerable dose may be equally effective. The findings may influence clinical guidelines for cancer prevention in hereditary high-risk populations.
Understand the Science
People with Lynch syndrome have a significantly increased risk of developing colorectal cancer and other types of cancer due to a hereditary predisposition. The CAPP2 study had already shown in this high-risk group that acetylsalicylic acid can significantly reduce the long-term risk of colorectal cancer. The study examined a comparatively high daily dose of 600 milligrams. The recently published international CaPP3 study now suggests that even a lower dose of 100 milligrams daily could have a similar cancer-preventive effect while causing fewer side effects, particularly bleeding complications. The research is published in The Lancet Gastroenterology & Hepatology journal.
Source: Aspirin rarely used for colorectal cancer prevention